[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission]

Clicks: 310
ID: 117028
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The arrival of new drugs and new therapeutic strategies allowed to reach sustained remission in an increasing number of patients with rheumatoid arthritis. The study of biologic disease-modifying anti-rheumatic drugs (bDMARDs) adaptation strategies is a need to optimize the benefit/risk balance and …
Reference Key
a2017la[discontinuation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mallick A;Fautrel B;Sagez F;Sordet C;Javier RM;Petit H;Chatelus E;Rahal N;Gottenberg JE;Sibilia J;;
Journal la revue de medecine interne
Year 2017
DOI
DOI not found
URL
https://www.pubmed.gov/28161110/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine Recurrence Remission Induction dose-response relationship drug arthritis rheumatoid / drug therapy* practice patterns antirheumatic agents / administration & dosage* pmid:28161110 doi:10.1016/j.revmed.2016.12.014 a mallick b fautrel j sibilia biological factors / administration & dosage biological products / administration & dosage* physicians' withholding treatment* / standards

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.